API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
BPL-003 is a novel, synthetic, patent-protected benzoate salt formulation of 5-MeO-DMT (mebufotenin) administered intranasally. It is being evaluated for the treatment of treatment resistant depression.
Lead Product(s): Mebufotenin
Therapeutic Area: Psychiatry/Psychology Product Name: BPL-003
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 24, 2024
Details:
BPL-003 (mebufotenin) is Beckley Psytech’s novel, synthetic, patent-protected benzoate salt formulation of 5-MeO-DMT (mebufotenin) and is administered intranasally. It is being evaluated for the treatment of treatment resistant depression.
Lead Product(s): Mebufotenin
Therapeutic Area: Psychiatry/Psychology Product Name: BPL-003
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2024
Details:
BMND08 (5-MeO-DMT) is a 5-HT1A receptor agonist, small molecule drug candidate. It is being evaluated for the treatment of depression & anxiety in alzheimer’s disease.
Lead Product(s): Mebufotenin
Therapeutic Area: Neurology Product Name: BMND08
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 29, 2024
Details:
The proceeds will advance short-duration psychedelic candidates, BPL-003 (mebufotenin), a novel, intranasal formulation of 5-methoxy-N,N-dimethyltryptamine, and ELE-101, a novel intravenous formulation of psilocin, by adding them to atai’s mental health innovation platform.
Lead Product(s): Mebufotenin
Therapeutic Area: Psychiatry/Psychology Product Name: BPL-003
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: ATAI Life Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing January 04, 2024
Details:
BPL-003, a novel synthetic formulation of 5-MeO-DMT (also known as mebufotenin), which is investigated for the treatment of treatment Resistant Depression (TRD).
Lead Product(s): Mebufotenin
Therapeutic Area: Psychiatry/Psychology Product Name: BPL-003
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2023
Details:
GH001, is formulated for mebufotenin (5-MeO-DMT) administration via a proprietary inhalation approach, which is investigated for the treatment of treatment-resistant depression.
Lead Product(s): Mebufotenin
Therapeutic Area: Psychiatry/Psychology Product Name: GH001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2023
Details:
BPL-003 (mebufotenin) is a psychoactive indolealkylamine derivative of tryptamine and binds to a variety of serotonergic 5-HT receptors which is considered to be the mechanism for its psychoactive effects.
Lead Product(s): Mebufotenin
Therapeutic Area: Psychiatry/Psychology Product Name: BPL-003
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2023
Details:
BMND08 is a proprietary sublingual formulation of 5-Metoxi-N,N-dimethyltryptamine ("5-MeO-DMT"), being investigated as a potential treatment of anxiety and depression in alzheimer’s disease.
Lead Product(s): Mebufotenin
Therapeutic Area: Psychiatry/Psychology Product Name: BMND08
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2023
Details:
BPL-003 (mebufotenin) is a psychoactive indolealkylamine derivative of tryptamine and binds to a variety of serotonergic 5-HT receptors which is considered to be the mechanism for its psychoactive effects.
Lead Product(s): Mebufotenin
Therapeutic Area: Psychiatry/Psychology Product Name: BPL-003
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2023
Details:
BPL-003 (mebufotenin) is a psychoactive indolealkylamine derivative of tryptamine and binds to a variety of serotonergic 5-HT receptors which is considered to be the mechanism for its psychoactive effects.
Lead Product(s): Mebufotenin
Therapeutic Area: Psychiatry/Psychology Product Name: BPL-003
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2023
Details:
BMND08 is an oral formulation of a natural psychedelic called 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) for the potential treatment of depression and anxiety in Alzheimer’s disease.
Lead Product(s): Mebufotenin
Therapeutic Area: Psychiatry/Psychology Product Name: BMND08
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 28, 2022
Details:
BPL-003, a proprietary intranasal formulation of synthetic 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT), for Treatment Resistant Depression. Phase I study earlier this year, showed that BPL-003 was well tolerated and pharmacokinetics and shortlasting pharmacodynamic effects.
Lead Product(s): Mebufotenin
Therapeutic Area: Psychiatry/Psychology Product Name: BPL-003
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2022
Details:
BPL-003, a synthetic intranasal formulation of 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT), which is under development for Treatment Resistant Depression and Alcohol Use Disorder.
Lead Product(s): Mebufotenin
Therapeutic Area: Psychiatry/Psychology Product Name: BPL-003
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2022
Details:
LSR-1019, is a best-in-class sublingual formulation of 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT), a fast-acting and rapidly clearing serotonergic psychedelic, in development for patients with treatment-resistant depression (TRD) and other severe neuropsychiatric disorders.
Lead Product(s): Mebufotenin
Therapeutic Area: Psychiatry/Psychology Product Name: LSR-1019
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: RA Capital Management
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing November 02, 2022
Details:
By partnering with Ksana Health, Beckley Psytech aims to track novel, predictive digital biomarkers to follow patient progress in upcoming Phase 2 evaluating the use of 5-MeO-DMT (BPL-003) in combination with psychotherapy in the treatment of treatment resistant depression.
Lead Product(s): Mebufotenin
Therapeutic Area: Psychiatry/Psychology Product Name: BPL-003
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ksana Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 14, 2022
Details:
BMND08 (5-Methoxy-N,N-dimethyltryptamine) novel drug candidate which may allow us to address a new line of development to attenuate depression and anxiety states in patients with Alzheimer’s-type cognitive impairment.
Lead Product(s): Mebufotenin
Therapeutic Area: Psychiatry/Psychology Product Name: BMND08
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
BPL-003 is a benzoate formulation of 5-MeO-DMT and is administered as a dry powder intranasal spray, may provide potential benefits in tolerability and absorption characteristics, and could potentially change the manner in which patients experience the treatment.
Lead Product(s): Mebufotenin
Therapeutic Area: Psychiatry/Psychology Product Name: BPL-003
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2022
Details:
Phase 1 trial is evaluating the safety and tolerability of a novel formulation of intranasal 5-methoxy-N,N-dimethyltryptamine, in treatment resistant depression (TRD) and other neuropsychiatric indications.
Lead Product(s): Mebufotenin
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2022
Details:
GH Research will use the proceeds to support further clinical development of GH001 (5-MeO-DMT) in Treatment-Resistant Depression (TRD) and to advance GH001 into further clinical development in additional psychiatric and neurological disorders.
Lead Product(s): Mebufotenin
Therapeutic Area: Psychiatry/Psychology Product Name: GH001
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: RA Capital
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing April 13, 2021
Details:
GH001 has the potential to offer an ultra-rapid clearance of symptoms with long-term sustained remission after a single administration session. In the completed Phase 1 healthy volunteer study (GH001-HV-101), GH001 was safe and well-tolerated at the investigated dose levels.
Lead Product(s): Mebufotenin
Therapeutic Area: Psychiatry/Psychology Product Name: GH001
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 19, 2020